The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).
 
J. Randolph Hecht
Honoraria - Amgen
Consulting or Advisory Role - Amgen
Research Funding - Amgen
Travel, Accommodations, Expenses - Amgen
 
Aleix Prat
Consulting or Advisory Role - NanoString Technologies
Research Funding - NanoString Technologies
 
Miklos Pless
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche
 
Antonio Cubillo
No Relationships to Disclose
 
Aitana Calvo
No Relationships to Disclose
 
Steven Raman
No Relationships to Disclose
 
Jason Alan Chesney
Consulting or Advisory Role - Amgen
Research Funding - Amgen; Bristol-Myers Squibb; Iovance Biotherapeutics
Travel, Accommodations, Expenses - Amgen
 
Chunxu Liu
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Emily Chan
Employment - Amgen
Stock and Other Ownership Interests - Amgen